Form 4: BioXcel Therapeutics Executive Javier Rodriguez Reports Stock Transactions
SEC Form 4
Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares.
Summary
- Javier Rodriguez, an executive at BioXcel Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On June 14, 2024, 521 shares of common stock were acquired through the vesting of restricted stock units (RSUs) and subsequently disposed of.
- On June 15, 2024, 562 shares of common stock were acquired through the vesting of RSUs and subsequently disposed of.
- On June 17, 2024, 361 shares were sold at a price of $1.2632 per share.
- Following these transactions, Rodriguez directly owns 8,394 shares of BioXcel Therapeutics common stock.
- The sales on June 17, 2024, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Rodriguez also holds 3,648 and 6,188 restricted stock units from grants on March 14, 2022, and March 15, 2023, respectively, which are vesting quarterly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine stock transactions under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.
Positives
- The executive's transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The sale of shares by an executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.
Risks
- Executive stock sales, even under a 10b5-1 plan, can sometimes create short-term downward pressure on the stock price.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, and are usually not significant unless they represent a large percentage of the executive's holdings or are timed suspiciously close to major company announcements.
Stakeholder Impact
- The stock sales could have a minor, temporary impact on shareholders due to potential price fluctuations.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter |
| 2023-12-14 | Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-06-14 | 521 shares acquired via RSU vesting and disposed of. |
| 2024-06-15 | 562 shares acquired via RSU vesting and disposed of. |
| 2024-06-17 | 361 shares sold at $1.2632 per share. |
| 2024-06-18 | Date of Form 4 filing. |
Keywords
BioXcel Therapeutics, BTAI, Form 4, Javier Rodriguez, Stock Transactions, Restricted Stock Units, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.